February 20, 2025
News
Römerberg, Germany and Gaithersburg, MD, USA (February 20, 2025) – Areterna LLC, a subsidiary of Synthgene-Bio and pioneer with innovative Nucleic Acid and RNA products, established for the purpose of providing raw materials and services tailored to mRNA and oligonucleotide therapeutics, has entered into a further distribution agreement with Bion2, a specialist and distributor of molecular biological products headquartered in Czech Republic. This partnership aims to enhance accessibility to high-quality, cost-effective raw materials and services for mRNA and oligo research and manufacturing in the Czech Republic, Poland, Hungary, Slovenia, Slovakia, Romania and Bulgaria.
The collaboration between Synthgene-bio, BIORON and Bion2 marks a further significant step towards globalization and access to important resources for mRNA and oligo research and manufacturing in East Europe. This strategic alliance is determined to benefit customers by providing them with enhanced access to vital materials necessary for the advancement of mRNA and oligo-related initiatives.
This agreement marks a pivotal moment in Areterna’s mission to democratize mRNA vaccines and therapeutics, highlighting the company’s dedication to delivering GMP-grade raw materials at competitive prices. Simon Koerpert, Senior Director of Business Development EU at Areterna LLC, emphasized the importance of this partnership, stating, “Through our extension with BIORON and Bion2, we anticipate expanding our presence in the fast-growing markets, and aiming to offer more affordable raw materials to support mRNA therapeutics development.”